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Xuefu Zhuyu Tang (XFZY), a famous formula in traditional Chinese medicine, has been demonstrated to show good 
therapeutic effects on diseases caused by blood stasis syndrome. Two of its eleven herbs, Radix Platycodonis and Radix 
Cyathulae, have been considered as Shi ingredients in the hierarchy of traditional formula compatibility and proven 
possessing synergistic properties that strengthen the formula's potency of activating blood circulation and resolving blood 
stagnation. However, its mechanism is still not clearly elucidated. In our previous study, we observed their effects on 
paeoniflorin pharmacokinetics of XFZY in rats. In this study, we continued by detecting and comparing their effect on the 
tissue distribution of paeoniflorin after oral administration of XFZY and its three variants (XFZY without Radix 
Platycodonis or/and Radix Cyathulae) in blood-stasis mice via HPLC assay. The results indicated that combining usage of 
Radix Platycodonis and Radix Cyathula increased the distribution of paeoniflorin in the lung and kidney and introduced the 
paeoniflorin into the liver, spleen and heart. It might explain their synergistic properties that strengthen the formula's effect 
of invigorating blood and dissolving stasis and provide experimental evidence to understand the pharmacological effects of 
Shi herbs in the hierarchy of traditional formula compatibility. 
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Blood stasis syndrome (BSS), an important 
pathological concept in traditional Chinese medicine 
(TCM)1,2, has been proven to correlate with the 
occurrence and development of a wide range of 
diseases such as coronary heart disease, hypertension, 
different types of cancer, diabetes, arrhythmia, 
obesity, dyslipidemia, gastric ulcer, hepatitis B, 
psoriasis, primary glomerular disease and rheumatoid 
arthritis3-5. With the ever-increasing prevalence of 
such diseases and the ever-emerging acceptance of 
complementary and alternative therapy, the use of 
TCM has become a worldwide trend6. Hence, TCM 
formulae of promoting blood circulation and 
removing blood stasis have been exploited as 
important therapeutic approaches.  
Xuefu Zhuyu Tang (XFZY), one of the most 
effective and commonly-used formulae for BSS7,8, 
was first recorded in the medical classic  
Correction of Errors in Medical Works by Qing-ren 
Wang (1768–1831)9. Its protective actions of 
reducing inflammation and oxidation, modulating 
angiogenesis, inhibiting platelet aggregation and 
improving hemorheology have been well 
documented10-13. This formula has become a focus 
of attention for many researches due to its favorable 
potency of activating blood circulation and 
dissolving blood stasis. It consists of 11 herbs that 
embody the compatibility principle of “Jun, Chen, 
Zuo, and Shi” (also known as “sovereign-minister-
assistant-courier”). In TCM, most formulae achieve 
their potency through actions between/among 
diverse ingredient herbs rather than a single  
herb. Hence, a critical issue for an optimized 
application of formulae is to understand their 
prescription compatibility.  —————— *Corresponding author 




In XFZY, Radix Platycodonis (Platycodon 
grandiflorum (Jacq.) A.DC.) and Radix Cyathulae 
(Cyathula officinalis KC Kuan) have been regarded as 
Shi (guide, messenger, conductant or envoy) 
ingredients that are to guide the action of the  
formula on the target channel or area of the body. 
Pharmacologically, they have been proven effective in 
increasing the formula's potency of activating blood 
circulation and resolving blood stagnation14, but its 
mechanism has not been fully elucidated. In our 
previous study, we observed their effects on 
paeoniflorin pharmacokinetics of XFZY in rats and 
revealed that combining usage of both herbs increased 
the absorption amount and rate of in rats and 
accelerated its elimination from the blood15. In this 
study, to provide more experimental evidence on the 
Shi herb in the hierarchy of TCM formula 
compatibility and optimize their clinical applications, 
we continued by detecting and comparing their effect 
on the tissue distribution of paeoniflorin after oral 
administration of XFZY and its three variants (XFZY 
without Radix Platycodonis or/and Radix Cyathulae) 
in blood-stasis mice via HPLC assay. 
 
Methodology 
 Animals  
A total of 48 SPF kunming mice (4 weeks of age, 
weighing 25±5 g, half male and half female), were 
obtained from Experimental Animal Center of 
Sichuan Biological Products Institute. All the 
experiments were conducted in accordance with the 
guidelines and ethics for the use of experimental 
animals and approved by the local Institutional 
Review Committee on Animal Care and Use. Four 
mice were kept in each cage and conditioned in a 
breeding room at 25℃ with a relative humidity of 
50%±10% under a dark/light cycle of 12 h. All mice 
were fed under the above conditions for one week 
with free access to water and rodent chow at all times. 
 Medicinal materials and reagents 
XFZY consists of Persicae Semen (Prunus persica 
(L.) Batsch and Prunus davidiana (Carr.) Franch.), 
Radix Angelicae Sinensis (Angelica sinensis Oliv. 
Diels), Rhizoma Chuanxiong (Ligusticum chuanxiong 
Hort), Flos Carthami (Carthamus tinctorius L.), Radix 
Paeoniae Rubra (Paeonia lactiflora Pall. and Paeonia 
veitchii Lynch), Radix Rehmanniae (Rehmannia 
glutinosa (Gaetn.) Libosch. ex Fisch. et Mey.), 
Fructus Aurantii (Citrus aurantium L), Radix Bupleuri 
(Bupleurum chinense DC. and Bupleurum 
scorzonerifolium Willd.), Radix Platycodonis, Radix 
cyathulae, and Radix et Rhizoma Glycyrrhizae 
(Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat., 
and Glycyrrhiza glabra L.) at differential ratio of 
12:9:4.5:9:6:9:6:3:4.5:9:6. All herbs, commercially 
available as dried matter, were purchased from 
Sichuan Ben Cao Tang Pharmaceutical Co., Ltd.  
with identification of two herbology professors  
(Chengdu, China). 
Paeoniflorin among several identified effective 
constituents of XFZY was considered the appropriate 
index for detection8,15. Paeoniflorin reference 
substance (purity 98%, batch No.: 121207) were 
obtained from Chengdu Pufei De Biotech Co.,  
Ltd.; Riboflavin reference substance (purity 98%, 
batch No.: 130114) were obtained from Chengdu 
PureChem-Standard Co., Ltd.; Glucan T500 was 
obtained from Beijing YaAnDa Biotechnology Co., 
Ltd.; and chromatographically pure carbinol and 
acetonitrile were required. 
 
Instruments and analytical conditions 
The instruments used were Ultraviolet-visible  
(UV-Vis) detector (SPD-10Avp); high performance 
liquid chromatography (HPLC, LC-10ATvp) (Shimadzu 
Corporation, Japan); FA1004 electronic scales 
(Shanghai liangping Instrument Co. Ltd. Shanghai, 
China); LG15-W high speed micro centrifuge (Beijing 
medical centrifuge factory, Beijing, China); WH-1 Mini 
vortex mixer (Shanghai Huxi Analytical Instrument Co. 
Ltd. Shanghai, China); Milli-Q water purification system 
(Millipore, Billerica, MI, USA). MVIS-2035 auto-
hemorheology analyzer (Chongqing Tianhai Medicare 
Instrument Co. Ltd. Chongqing, China). 
The chromatographic separation was obtained  
on Diamonsil C18 chromatographic column (250 
mm×4.6 mm, 5 µm). The chromatographic 
conditions were recorded as follows: injection 
volume was 20 µL; chromatograms were monitored 
at 230 nm; column temperature was maintained at 
30℃; mobile phase consisted of acetonitrile and 
water (16:84) with a flow rate of 1.0 mL min-1; and 
the geniposide were set as internal standard 
substance. 
 
Preparation of medicinal solution 
According to the traditional formulae, the amount 
of 78 g XFZY, 73.5 g XFZY-JG (XFZY without 
Radix Platycodonis), 69 g XFZY-NX (XFZY without 
Radix Cyathulae), and 64.5 g XFZY-JG-NX (XFZY 
without Radix Platycodonis and Radix Cyathulae) 
were multiplied by 45 to 3 510 g, 3 307.5 g, 3 105 g, and 
2 902.5 g, respectively, and immersed in 35 100 mL,  




33 075 mL, 31 050 mL, and 29 025 mL of water (v/v, 
1:10), respectively, for 30 min at room temperature. 
XFZY, XFZY-JG, XFZY-NX, and XFZY-JG-NX 
were decocted 30 min for 3 times, respectively. After 
filtration and concentration in a rotatory evaporator 
for 8 h, the aqueous extract of each sample was dried 
at 45ºC in a vacuum drying oven to obtain 426 g 
original extract powder for XFZY, 1 054 g for XFZY-
JG, 948 g for XFZY-NX, and 650 g for XFZY-JG-
NX. The mass fraction of paeoniflorin in original 
extract powder was 2.290 mg g-1 for XFZY, 2.620 mg 
g-1 for XFZY-JG, 3.366 mg g-1 for XFZY-NX, and 
3.120 mg g-1 for XFZY-JG-NX. An amount of 4 g 
extractive powder of each sample was accurately 
weighed, dissolved in 4.0 mL, 4.6 mL, 5.9 mL,  
and 5.4 mL of water, and swirled to mix  
thoroughly and obtain 4 medicinal solutions for  
oral gavage. 
Glucan T500 solution at concentration of 25% was 
prepared by dissolving 1.0 g Glucan T500 in 4 mL  
of 0.9% sodium chloride injection. All solutions were 
stored at 0°C until analysis. 
 Preparation of stock solutions and quality control samples 
Paeoniflorin stock solution was prepared by 
dissolving 6.63 mg paeoniflorin in 90% methanol 
aqueous solution at concentration of 130.0 µg mL-1. 
Internal standard stock solution was prepared by 
dissolving 1.82 mg geniposide in 90% methanol 
aqueous solution at concentration of 35.67 µg mL-1. 
Internal working standard solution was prepared by 
diluting 12.5 mL stock solution 90% methanol 
aqueous solution at concentration of 8.92 mg L-1. 
Quality control (QC) samples were prepared in the 
same manner at paeoniflorin concentrations of 
0.0208, 0.26, and 2.6 mg L-1 for the lung, 0.026, 
0.208, and 2.08 mg L-1 for the kidney, and 0.026, 
0.208, and 2.08 mg L-1 for the serum. All solutions 
were stored at 0°C until analysis. 
 
Method validation 
Specificity: The specificity of this method was 
investigated by comparing chromatograms of blank 
kidney, lung, and serum homogenate samples; blank 
kidney, lung, and serum homogenate samples spiked 
with standard solution and IS; and treated kidney, 
lung, and serum homogenate samples.  
Linearity and quantification: Calibration curves 
were obtained by linear regression of the peak area 
ratio of paeoniflorin to IS (Y-axis) and the standard 
concentration, which constituted the range of the 
calibration curve (X-axis). The calibration line was 
corrected by a weighted factor (1/X2), described as 
Y=a+bX. Each QC sample was recalculated using the 
calibration curve.  
Precision and accuracy: Accuracy and precision 
of the method were determined by repeat analyses of 
QC samples. The intraday precision and accuracy 
were evaluated by determining QC samples five times 
within a single day, whereas the interday precision 
and accuracy were assessed by determining QC 
samples over three consecutive days. 
Recovery rate: The recovery of paeoniflorin was 
performed by comparing the peak area of the added 
paeoniflorin in kidney, lung, and serum homogenates 
with the same amount of paeoniflorin added to the 
mobile phase. QC samples at three concentrations 
were evaluated in the recovery experiments (n=5 for 
each QC). 
Stability: The stability was evaluated by measuring 
QC samples at three concentrations under different 
conditions (𝑛=4 for each QC). Freezing thawing 
stability was investigated after QC samples underwent 
three cycles of freezing at −20℃ freezer and thawing 
at 37℃ water bath; the short-term stability was 
assessed by exposing QC samples at room 
temperature for 8 h; and the long-term stability was 
estimated after storing QC samples at −20ºC for 7 d.  
 
Tissue distribution assay 
Animal groupin: Mice were randomized into two 
groups: normal group and blood-stasis model group, 
with 24 in each group. Then, mice in each group were 
randomly sub-assigned to 4 groups, with 6 in each 
sub-group.  
Animal experimental model: The animals were 
fasting for 12 h and allowed free access to water 
before modeling. A 25% glucan T500 solution  
(20 mL kg-1) was injected intravenously through 
caudal vein of the mice in the blood-stasis model 
group, and 0.9% physiological saline for the normal  
group. The level of whole blood viscosity,  
plasma viscosity, hematocrit, and fibrinogen were 
7.08±0.89 mPa s (200 s-1), 2.23±0.37 mPa s  
(200s-1), 65.46±8.46 %, and 7.25±0.68 g/L in the 
blood-stasis group.  
Medicinal solution administration: Ten minutes 
after modeling, mice in the normal and the blood 
stasis group were treated orally with 6 mL kg-1 of 
XFZY, XFZY-JG, XFZY-NX, and XFZY-JG-NX 
solution, respectively. Each group was administered 
equal volume of paeoniflorin at 13.742 mg kg-1. 




Specimen collection and processing: The mice 
were sacrificed 30 min after administration. Tissues 
including the heart, liver, spleen, lung, and kidney 
were obtained from each mouse, cleaned with 0.9% 
physiological saline, absorbed by filter paper, 
weighed, and homogenized in normal saline solution 
(250 mg/mL). The obtained tissue homogenates were 
stored separately at -20℃. 
Before analyzing, 90% methanol aqueous solution 
was added to the liver, lung, and kidney (4 mL g-1); 
and heart and spleen (8 mL g-1). For each sample,  
20 𝜇L working internal standard solution was added 
to 500 𝜇L tissue homogenate. The mixtures were 
vortexed for 20 s and centrifuged at 10 000 r min-1 for 
10 min. Supernatant of each sample was transferred 
into a 1.5 mL centrifuge tube individually and 
evaporated under nitrogen in a water bath at 40ºC, and 
100 µL of water were added for redissolution. The 
obtained samples were centrifuged at 10 000 r min-1 for 
10 min. Finally, 20 𝜇L supernatant of each sample 
was taken for analysis. 
 
Data analysis 
Statistical analysis was performed using the SPSS 
13.0 software and the data were presented as the 
standard error of the mean. The concentration-peak 
area curves of paeoniflorin were obtained through the 
DAS 2.0 software (Shanghai, China). Comparisons on 
peak area and concentration ratio of paeoniflorin 
between two groups were statistically evaluated by 
the Mann-Whitney U test; the concentration of 
paeoniflorin was changed into napierian logarithm 
and evaluated by a one-way analysis of variance 






Specificity: Representative chromatograms were 
shown in Fig. 1. The paeoniflorin and endogenous 
impurities were confirmed separate well, the degree 
of separation was found to be 1.8, and the retention 
time was 15.9 min for paeoniflorin and 9.5 min for 
internal standard substance. 
Linearity and sensitivity: The equation for the 
calibration curves and linear range of paeoniflorin 
were presented in Table 1. The range of calibration 
curves were shown in Fig. 2. Results showed that 
calibrations curves were linear and acceptable. The 
range of concentration and limits were suitable for the 
tissue distribution study of paeoniflorin. 
Precision and accuracy: The precision was 
presented as the relative standard deviation (RSD), 
the data of intra-day and inter-day accuracy and 
precision of paeoniflorin were demonstrated in Table 
2. The results showed the intra-accuracy ranged from 
-2.5% to 1.8%, the inter-accuracy -1.4% to 1.4%, the 
intra-precision 1.7% to 3.1%, and the inter-precision 
1.9% to 3.0%. It indicated that the precision and 
accuracy of the present method were within the 
acceptable limits. 
Recovery: The extraction recoveries were 
presented in Table 2. Data revealed that the lung 
samples was well within 62.1%~89.0%; the kidney 
samples was well within 67.7%~90.7%; and the 
serum samples was well within 80.6%~87.4%. The 
SD of extraction recoveries was 0.8%~6.9% for the 
lung samples, 2.0%~3.1% for the kidney samples, and 
1.7%~5.5% for the serum samples. 
Stability: The results of stability under different 
storage conditions were presented in Table 3. Results 
revealed that samples were stable under various 
experimental conditions. 
 
Tissue distribution assay 
A validated HPLC method was applied to 
investigate paeoniflorin distribution in the heart, liver, 
spleen, kidney, and lung of blood-stasis mice 30 min 
after oral administration of XFZY and its three 
variants. The data of tissue distribution and statistical 
analysis were presented in Table 4.  
The results displayed that upon the comparison 
with XFZY-JG-NX, sole usage of Radix 
Platycodonis (XFZY-NX) increased the distribution 
concentration of paeoniflorin in the kidney of normal 
group, and the lung/serum concentration rate and 
distribution of paeoniflorin in the lung and kidney  
of blood-stasis group; sole usage of Radix Cyathulae 
(XFZY-JG) introduced the paeoniflorin into the 
tissue of heart, liver, and spleen in the blood-stasis 
group; and combing usage of Radix Platycodonis 
and Radix Cyathulae (XFZY) increased the 
lung/serum concentration rate and distributed more 
paeoniflorin into the tissue of heart, liver and spleen 
in the blood-stasis group. The comparisons between 
the normal and the blood-stasis group were also 
performed for XFZY and its three variants. The 
findings revealed that in the blood-stasis group, the 
combing usage of Radix Platycodonis and Radix 
Cyathulae (XFZY) significantly increased the 
lung/serum ratio and the concentration of 
paeoniflorin in the lung and kidney and distributed 




the paeoniflorin into more tissues, including liver, 
spleen and heart; sole usage of Radix Cyathulae 
(XFZY-JG) increased the concentration of 
paeoniflorin in the lung and kidney, and distributed 
the paeoniflorin into the tissue of heart, liver, spleen; 
sole usage of Radix Platycodonis (XFZY-NX) 
increased the lung/serum ratio and the kidney/serum 
ratio and uplifted the concentration of paeoniflorin in 
the lung and kidney; removal of both Radix 
Platycodonis and Radix Cyathulae (XFZY-JG-NX) 
increased the kidney/serum ratio and the 
concentration of paeoniflorin in the kidney, whereas 
decreased the lung/serum ratio and the concentration 
of paeoniflorin in the lung. 
 
 
  Fig. 1 — HPLC chromatograms of paeoniflorin (t/min) (a), reference substance (b), blank serum (c), serum (d), blank kidney (e), kidney 
(f), blank lung (g), lung. (1) paeoniflorin, (2) internal standard substance. 
 





Formula is the major form of TCM's clinical 
application and its potency is attributable to the 
synergistic and/or additive action between/among 
diverse ingredient herbs. Hence, to reveal the 
scientificity and rationality of its compatible rank is of 
great importance for uncovering the compatibility 
myth of the formula and optimizing its clinical 
application. Among the four ranks of the ingredients 
in the hierarchy of formula compatibility, Shi (guide, 
messenger, conductant or envoy) is capable of 
directing the actions of the formula to the target 
channel or areas of the body and reflects the selective 
therapeutic effects of Chinese medicinals on a certain 
area or tissue of the body. It is crucial for the 
therapeutic effect of a formula and has been the focus 
of increasing researches. In this study, we validated 
the effect of Shi ingredients in the context of a 
formula. The effect Radix Platycodonis or/and  
Radix Cyathulae on the tissue distribution of 
paeoniflorin in blood-stasis mice was investigated 
through "decomposing formula" (removing Radix 
Platycodonis or/and Radix Cyathulae from XFZY) 
and comparing XFZY with its three variants.  
XFZY has been proven effective in treating  
various diseases caused by BSS16-20. Among its 11 
ingredients, Radix Platycodonis and Radix Cyathulae 
have been categorized into the Shi ranking. They are 
potent in improving XFZY's effect of invigorating 
blood circulation and removing blood stasis14. 
Traditionally, the former is bitter, acrid and neutral, 
enters the lung and carries the effect of other herbs 
upwards; whereas the latter is bitter, sweet, sour and 
neutral, enters the kidney and liver and conducts 
blood downwards. In this study, we demonstrated 
under the blood-stasis state, combining use of Radix 
 
Table 1 — Calibration curves and linear range of paeoniflorin 
Compound Tissue Calibration curves Correlation coefficient (r)  Linear rang (ng/mL) 
Paeoniflorin 
Serum Y = 17 748.848X－200.472 r = 0.999 1 0.026~2.08 
Lung Y = 17 663.323X－300.424 r = 0.999 7 0.0208~2.60 
Kidney Y = 17 721.875X－291.167 r = 0.999 9 0.026~2.08 
 
Table 2 — Intra-assay and Inter-assay precision, accuracy, and recovery of paeoniflorin in the serum, lung, and kidney 
Compound Tissue QC 
Concentration 
Intraday Interday Recovery 
(mg/L) Precision (%) Accuracy (%)  Precision (%) Accuracy (%) (%, mean SD) 
Paeoniflorin 
Serum 0.026 2.9 0.1 2.6 0.1 87.4 5.5 
0.208 2.8 1.0 2.0 1.0 80.6 2.0 
2.08 3.1 -0.1 3.0 0.0 87.1 1.7 
Lung 0.0208 2.8 -2.5 2.2 -1.4 62.1 6.9 
0.26 2.9 1.8 2.7 0.7 83.1 0.8 
2.6 2.0 0.7 2.0 0.9 89.0 1.9 
Kidney 0.026 2.6 -0.5 2.4 0.1 67.7 2.0 
0.208 1.7 -2.1 1.9 -1.4 84.7 2.9 
2.08 2.5 1.2 2.1 1.4 90.7 3.1 
 
Table 3 — Stability of paeoniflorin in the serum, lung, and kidney (n=4) 
Compound Tissue QC 
Concentration 
Freeze-thaw stability Short-term stability Long-term stability 
(mg/L) Mean  SD RE (%)  Mean  SD RE (%)  Mean  SD RE (%) 
Paeoniflorin 
Serum 0.026 0.0248 0.0011 -4.6 0.0261 0.0005 0.4 0.0257 0.0003 -1.2 
0.208 0.2062 0.0072 -0.9 0.2078 0.0018 -0.1 0.2082 0.0032 0.1 
2.08 2.0136 0.0821 -3.2 2.1061 0.0235 1.3 2.0348 0.0508 -2.2 
Lung 0.0208 0.0198 0.0010 -4.8 0.0221 0.0004 6.3 0.0207 0.0001 -0.3 
0.26 0.2538 0.0085 -2.4 0.2611 0.0034 0.4 0.2648 0.0026 1.9 
2.6 2.6986 0.1011 3.8 2.6155 0.0205 0.6 2.5146 0.0461 -3.3 
Kidney 0.026 0.0278 0.0009 6.9 0.0254 0.0004 -2.3 0.0268 0.0003 2.9 
0.208 0.1996 0.0131 -4.0 0.2064 0.0065 -0.8 0.2086 0.0035 0.3 
2.08 1.9748 0.0328 -5.1 2.021 0.0141 -2.8 1.9555 0.0236 -6.0 
 




Platycodonis and Radix Cyathula exerted significant 
effects on the distribution of paeoniflorin in the lung 
and kidney, which is consistent with the TCM 
wisdom. Sole usage of Radix Platycodonis also 
presented an effect on the kidney, while using Radix 
Cyathula solely or together with Radix Platycodonis 
introduced the paeoniflorin into more tissues, 
including the heart, liver and spleen. Herein, we infer 
the therapeutic effect of the Shi herbs may be 
attributed to their influences on the tissue distribution 
of the effective constituent. 
In TCM, the human body is an integrated and 
balanced whole; all the component parts are 
interconnected via channels. The amount of medicinal 
concentration found in a tissue is also closely 
correlated with its concentration in the serum. 
Therefore, we detected both indexes and further 
calculated the lung-serum concentration ratio 
(paeoniflorin concentration in the lung/paeoniflorin 
concentration in the serum) and kidney-serum 
concentration ratio (paeoniflorin concentration in the 
kidney/paeoniflorin concentration in the serum). The 
  








results demonstrated that sole usage of Radix 
Platycodonis or Radix Cyathula, and combining 
Radix Platycodonis with Radix Cyathula increased 
the lung-serum and kidney-serum concentration ratio. 
Herein, we infer that the accelerated ratio may imply 
an increased distribution of the active constituents 
from the blood to the tissues. 
Syndrome (zheng, pattern) is the abstraction and 
generalization of the pathological changes at a certain 
stage of disease21, which reflects the changes of multi-
system of the human body and provides further 
stratification of the patient's condition. It is the target of 
treatment and the underlying principle for the TCM's 
strategy of "different treatments for same disease, and 
same treatment for different diseases". The key to 
utilizing TCM appropriately and maximizing its efficacy 
is to accurately interpret syndrome. Therefore, the 
establishment and adoption of animal model that reflects 
certain syndrome is of great importance in the 
pharmacological research of TCM. In this study, the 
mouse model used was a simulation of the BSS, and the 
results presented that for the same formula, significant 
differences on peak area of paeoniflorin and 
concentration of paeoniflorin in different tissues were 
noted between the normal group and the BSS group 
(p＜0.05). BSS exerted influences on the tissue 
distribution of paeoniflorin, hence the adoption of 
syndrome-based experimental animal is necessary for 
the performing corresponding pharmacokinetic studies. 
 
Conclusion 
This study validated that for BSS, combining usage 
of Radix Platycodonis and Radix cyathulae in XFZY 
could fortify the distribution of paeoniflorin in the lung 
and kidney, which are consistent with TCM wisdom. 
Moreover, they could distribute the paeoniflorin into 
more tissues, including the heart, liver and spleen. This 
may partly explain why combination of these two herbs 
demonstrated a more potent effect on activating blood 
flow and relieving blood stasis.  
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